Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy ...

Credit: Canadian Light Source The researchers found that when the Ras protein is in its mutated, cancer-causing state, "molecules snuggle inside the pocket. Using crystallography, we were able to ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

KRAS G12C is one of several genetic mutations known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer cases, but ...

The KRAS G12D mutation is the most common oncogenic KRAS variant, identified in approximately 34% of pancreatic ductal adenocarcinoma cases, 12% of colorectal cancers and 4% of lung adenocarcinomas.

They also performed in vitro experiments with human fibroblast cell lines, investigating the effects of inhibiting both the protein and the KRAS gene, and observed deactivation of these cells ...

Dr. Steven LaPlante, a professor at Quebec's Institut National de la Recherche Scientifique (INRS), and his team studied a type of protein called Ras, "which is highly related to a good percentage ...